Vizora日本語

Sumitomo ChemicalSUMITOMO CHEMICAL COMPANY, LIMITED4005東証プライム化学FY ending Mar 2026, consolidated, IFRS

Sumitomo Chemical FY ending Mar 2026 results

About 29% of Sumitomo Chemical's sales come from Essential and Green Materials, with ICT and Mobility Solutions and Agro and Life Solutions making up much of the rest.

Out of every ¥100 of sales, about ¥7 is left as operating profit.

Revenue changed -10.7% from the prior year, operating profit -21.4%.

Revenue and profit pattern

Revenue and profit down

Revenue -10.7% · profit -21.4%, calculated from disclosed figures.

Operating leverage: 2.01× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2025 → FY ending Mar 2026

Revenue
-10.7%¥2.61T → ¥2.33T
Gross profit
-7.9%¥725.5B → ¥668.3B
Operating income
-21.4%¥193B → ¥151.7B
Net income attributable to owners
+57.9%¥38.6B → ¥60.9B
Operating cash flow
+0.7%¥233B → ¥234.8B

Results at a glance

  • Revenue for the FY ending Mar 2026 was ¥2.33T, down -10.7% from ¥2.61T.
  • Operating income fell -21.4% to ¥151.7B, mainly because a one-off gain tied to Petro Rabigh, its Saudi joint venture, did not repeat.
  • Net income attributable to owners still rose +57.9% to ¥60.9B, since last year's loss from forgiving loans to Petro Rabigh was gone.
  • Operating cash flow held steady at ¥234.8B, up +0.7%.

What drove the change

  • Essential and Green Materials sold much less: Petro Rabigh shut down for scheduled maintenance, and the company had exited aluminum and sold part of its plastics business.
  • Sumitomo Pharma grew in North America on sales of the prostate cancer drug Orgovyx and the overactive bladder drug Gemtesa, while restructuring cut its spending, including R&D.
  • ICT and Mobility Solutions was held back by lower prices for display materials and a stronger yen.

Things to watch

  • Naphtha, the main feedstock for its petrochemicals, can jump in price with Middle East tensions, and profits suffer if price increases reach customers late.
  • A stronger yen shrinks export earnings and the yen value of overseas subsidiaries' profits.
  • Sumitomo Pharma's drug pipeline may not reach approval on schedule, and drug price controls in Japan, the US and China could weigh on sales.

Annual securities report (FY ending Mar 2026) / 経営者による財政状態、経営成績及びキャッシュ・フローの状況の分析 · Annual securities report (FY ending Mar 2026) / 事業等のリスク

Where the money goes

FY ending Mar 2025 → FY ending Mar 2026

Where ¥100 of sales goes

For every ¥100 Sumitomo Chemical sells, how much goes where, and how much is kept.

FY ending Mar 2026
Cost of sales
¥71
SG&A
¥24
Other costs
¥2
Operating profit
¥7
Net profit kept
¥3

Annual margin trends

Gross margin28.7%
FY ending Mar 2021: 33.7%33.7%FY ending Mar 2022: 31.6%31.6%FY ending Mar 2023: 28.4%28.4%FY ending Mar 2024: 20.4%20.4%FY ending Mar 2025: 27.8%27.8%FY ending Mar 2026: 28.7%28.7%FY21FY22FY23FY24FY25FY26
Operating margin6.5%
FY ending Mar 2021: 6.0%6.0%FY ending Mar 2022: 7.8%7.8%FY ending Mar 2023: -1.1%-1.1%FY ending Mar 2024: -20.0%-20.0%FY ending Mar 2025: 7.4%7.4%FY ending Mar 2026: 6.5%6.5%FY21FY22FY23FY24FY25FY26
Net margin2.6%
FY ending Mar 2021: 2.0%2.0%FY ending Mar 2022: 5.9%5.9%FY ending Mar 2023: 0.2%0.2%FY ending Mar 2024: -12.7%-12.7%FY ending Mar 2025: 1.5%1.5%FY ending Mar 2026: 2.6%2.6%FY21FY22FY23FY24FY25FY26

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2026

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第145期(2025/04/01－2026/03/31)

    ID S100YAUO2026-06-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第144期(2024/04/01－2025/03/31)

    ID S100VXZW2025-06-20Open

  • EDINET (FSA Japan)

    有価証券報告書－第143期(2023/04/01－2024/03/31)

    ID S100TMMW2024-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第142期(2022/04/01－2023/03/31)

    ID S100QXTB2023-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第141期(令和3年4月1日－令和4年3月31日)

    ID S100O9HK2022-06-23Open

  • EDINET (FSA Japan)

    有価証券報告書－第140期(令和2年4月1日－令和3年3月31日)

    ID S100LJNG2021-06-23Open

Extracted from XBRL: 43

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image